Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
To find a recommended dose of the combination of alpelisib and pembrolizumab that can be given to patients with metastatic breast cancer or melanoma.
Trial Details
- NCT ID
- NCT06545682
- Phase
- PHASE1
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Cancer Type
- Brain Cancer
- Interventions
- Alpelisib + Pembrolizumab
- Locations (sample)
- Houston, Texas, United States|29.76328,-95.36327
Key Eligibility Criteria
- Patients must be 18 years or older.
- Patients must be willing and able to provide informed consent.
- In the dose escalation, patients must have histologically documented locally advanced, unresectable, or metastatic melanoma or TNBC that has progre…
- In the dose expansion, patients must have histologically documented locally advanced, unresectable, or metastatic melanoma or TNBC that has progres…
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Brain Cancer Trials on Trialify →